Burden of transmitted multidrug resistance in epidemics of tuberculosis: A transmission modelling analysis

The Lancet Respiratory Medicine

Volumn 3, Issue 12, 2015, Pages 963-972

  Kendall, Emily A ^a   Fofana, Mariam O ^b   Dowdy, David W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL STRAIN; BANGLADESH; BAYES THEOREM; CALIBRATION; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG SENSITIVITY; EPIDEMIC; FUNDING; HUMAN; INCIDENCE; MATHEMATICAL MODEL; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PERSON TO PERSON TRANSMISSION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SIMULATION; TRANSMISSION MODELLING ANALYSIS; TREATMENT RESPONSE; UZBEKISTAN; STATISTICAL MODEL; TRANSMISSION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EPIDEMICS; HUMANS; MODELS, STATISTICAL; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84947313147     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00458-0     Document Type: Article

References (49)

1. Global tuberculosis report 2014 2014, WHO, World Health Organization, Geneva, (accessed Oct 23, 2014). http://www.who.int/tb/publications/global_report/en/.
2. Dye C, Garnett GP, Sleeman K, Williams BG Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet 1998, 352:1886-1891.
3. Drug-resistant TB: surveillance and response. Supplement: global tuberculosis report 2014 2014, WHO, World Health Organization, Geneva, (accessed Oct 26, 2015). http://www.who.int/tb/publications/global_report/gtbr14_supplement_web_v3.pdf.
4. Dye C, Williams BG Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci USA 2000, 97:8180-8185.
5. Suen S, Bendavid E, Goldhaber-Fiebert JD Disease control implications of India's changing multi-drug resistant tuberculosis epidemic. PLoS One 2014, 9:e89822.
6. Blower SM, Chou T Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004, 10:1111-1116.
7. Brigden G, Nyang'wa B-T, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ 2014, 92:68-74.
8. Cohen T, Colijn C, Wright A, Zignol M, Pym A, Murray M Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med 2008, 177:1302-1306.
9. Clark TG, Mallard K, Coll F, et al. Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One 2013, 8:e83012.
10. Dantas NGT, Suffys PN, da Silva Carvalho W, et al. Genetic diversity and molecular epidemiology of multidrug-resistant Mycobacterium tuberculosis in Minas Gerais State, Brazil. BMC Infect Dis 2015, 15:306.
11. Merker M, Blin C, Mona S, et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 2015, 47:242-249.
12. Murray M, Alland D Methodological problems in the molecular epidemiology of tuberculosis. Am J Epidemiol 2002, 155:565-571.
13. Shrestha S, Knight GM, Fofana M, et al. Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis. Open Forum Infect Dis 2014, 1:ofu073.
14. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci USA 2008, 105:11293-11298.
15. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011 2011, WHO, World Health Organization, Geneva, (accessed March 21, 2013). http://whqlibdoc.who.int/publications/2011/9789241501330_eng.pdf.
16. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009, 6:e1000146.
17. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009, 6:e1000150.
18. Tiemersma EW, van der Werf MJ, BorgdorffMW, Williams BG, Nagelkerke NJD Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011, 6:e17601.
19. Vynnycky E, Fine PE The annual risk of infection with Mycobacterium tuberculosis in England and Wales since 1901. Int J Tuberc Lung Dis 1997, 1:389-396.
20. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012, 54:784-791.
21. Horsburgh CR, O'Donnell M, Chamblee S, et al. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 2010, 182:420-425.
22. Fox GJ, Barry SE, Britton WJ, Marks GB Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 2013, 41:140-156.
23. Corbett EL, Bandason T, Cheung YB, et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007, 4:e22.
24. Okada K, Onozaki I, Yamada N, et al. Epidemiological impact of mass tuberculosis screening: a 2-year follow-up after a national prevalence survey. Int J Tuberc Lung Dis 2012, 16:1619-1624.
25. Global tuberculosis report 2013 2013, WHO, World Health Organization, Geneva.
26. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999, 353:444-449.
27. Lan NTN, Lademarco MF, Binkin NJ, Tung LB, Quy HT, Cĵ NV A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2001, 5:575-578.
28. He GX, Xie YG, Wang LX, et al. Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS One 2010, 5:e10799.
29. Espinal MA, Kim S, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283:2537-2545.
30. Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis 2014, 58:1676-1683.
31. McKay MD, Beckman RJ, Conover WJ A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics 1979, 21:239.
32. Grandjean L, Gilman RH, Martin L, et al. Transmission of multidrug-resistant and drug-susceptible tuberculosis within households: a prospective cohort study. PLoS Med 2015, 12:e1001843.
33. Poole D, Raftery AE Inference for deterministic simulation models: the Bayesian melding approach. J Am Stat Assoc 2000, 95:1244-1255.
34. Glaziou P, Falzon D, Floyd K, Raviglione M Global epidemiology of tuberculosis. Semin Respir Crit Care Med 2013, 34:3-16.
35. Marais BJ, Mlambo CK, Rastogi N, et al. Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol 2013, 51:1818-1825.
36. Lanzas F, Karakousis PC, Sacchettini JC, Ioerger TR Multidrug-resistant tuberculosis in Panama is driven by clonal expansion of a multidrug-resistant Mycobacterium tuberculosis strain related to the KZN extensively drug-resistant M. tuberculosis strain from South Africa. J Clin Microbiol 2013, 51:3277-3285.
37. Yang C, Shen X, Peng Y, et al. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clin Infect Dis 2015, 61:219-227.
38. Barletta F, Otero L, de Jong BC, et al. Predominant Mycobacterium tuberculosis families and high rates of recent transmission among new cases are not associated with primary multidrug resistance in Lima, Peru. J Clin Microbiol 2015, 53:1854-1863.
39. Wang Q, Lau SKP, Liu F, et al. Molecular epidemiology and clinical characteristics of drug-resistant Mycobacterium tuberculosis in a tuberculosis referral hospital in China. PLoS One 2014, 9:e110209.
40. Jenkins HE, Plesca V, Ciobanu A, et al. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J 2013, 42:1291-1301.
41. Lin H, Shin S, Blaya JA, et al. Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting. Epidemiol Infect 2011, 139:1784-1793.
42. Sterling TR Drug-resistant tuberculosis in New York City: lessons to remember. Clin Infect Dis 2006, 42:1711-1712.
43. Lemaine V Treatment and management of MDR-TB in Latvia. Bull World Health Organ 2007, 85:325.
44. Laurence YV, Griffiths UK, Vassall A Costs to health services and the patient of treating tuberculosis: a systematic literature review. Pharmacoeconomics 2015, 33:939-955.
45. Narendran G, Menon PA, Venkatesan P, et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis 2014, 59:1798-1804.
46. Middelkoop K, Mathema B, Myer L, et al. Transmission of tuberculosis in a South African community with a high prevalence of HIV infection. J Infect Dis 2015, 211:53-61.
47. Andrews JR, Gandhi NR, Moodley P, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 2008, 198:1582-1589.
48. Cain KP, Marano N, Kamene M, et al. The movement of multidrug-resistant tuberculosis across borders in East Africa needs a regional and global solution. PLoS Med 2015, 12:e1001791.
49. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012, 366:2161-2170.